Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azilsartan Medoxomil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 2/20 | 0.49 |
| ▸ | AGTR2 | P50052 | 3/20 | 1.00 |
| ▸ | PPARG | P37231 | 3/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.45 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azilsartan Medoxomil SCHEMBL683374 | 1.00 | AGTR2 (1.00) | AGTR2PPARGABCB11CYP3A4AGTR1 | |
| Azilsartan Medoxomil SCHEMBL967309 | 0.99 | AGTR2 (0.99) | AGTR2PPARGABCB11CYP3A4AGTR1 | |
| Azilsartan Medoxomil SCHEMBL967313 | 0.99 | AGTR2 (0.99) | AGTR2PPARGABCB11CYP3A4AGTR1 | |
| Azilsartan Medoxomil SCHEMBL968583 | 0.99 | AGTR2 (0.99) | AGTR2PPARGABCB11CYP3A4AGTR1 | |
| Azilsartan Medoxomil SCHEMBL30770646 | 0.99 | AGTR2 (0.99) | AGTR2PPARGABCB11CYP3A4AGTR1 | |
| Azilsartan Medoxomil SCHEMBL965769 | 0.99 | AGTR2 (0.99) | AGTR2PPARGABCB11CYP3A4AGTR1 | |
| Azilsartan Medoxomil SCHEMBL965772 | 0.99 | AGTR2 (0.99) | AGTR2PPARGABCB11CYP3A4AGTR1 | |
| SCHEMBL18405788 | 0.95 | AGTR2 (0.91) | AGTR2PPARGABCB11CYP3A4AGTR1 | |
| SCHEMBL683700 | 0.94 | AGTR2 (0.90) | AGTR2PPARGABCB11CYP3A4AGTR1 | |
| SCHEMBL15456840 | 0.93 | AGTR2 (0.87) | AGTR2PPARGABCB11CYP3A4AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025122600-A1 | COMPOSITIONS AND METHODS FOR TREATING ABERRANT NITROSYLATION | CASE WESTERN RESERVE UNIVERSITY (US) | 2025-06-12 | — | — | WO | disclosed |
| WO-2022173818-A1 | USE OF BILIVERDIN REDUCTASE B INHIBITORS TO ALLOW MALARIA ERADICATION IN PATIENTS WITH G6PD DEFICIENCY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2022-08-18 | — | — | WO | disclosed |